Stay fully informed. Get the latest news from Brooklyn ImmunoTherapeutics.

July 26, 2022

Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer

June 17, 2022

Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

June 7, 2022

Brooklyn ImmunoTherapeutics Announces Board Changes

May 31, 2022

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

April 15, 2022

Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results

March 9, 2022

Brooklyn ImmunoTherapeurics Announces Closing of $12 Million Private Placement

March 7, 2022

Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement

January 20, 2022

Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

January 13, 2022

Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio

December 17, 2021

Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index